[Show abstract][Hide abstract] ABSTRACT: Nevirapine, a NNRTI was proven effective in differentiation of transformed cells by arresting the reverse transcriptase activity of telomerase in transformed cells. According to a recent hypothesis, almost all NNRTI functions by a similar mechanism against HIV-1 RT. The presence of evolutionary conserved regions between HIV- 1 RT and hTERT, a catalytic subunit of telomerase also implies the importance of those regions in reverse transcriptase activity. Such evolutionary conserved regions and Nevirapine’s activity against cancer cell proliferation will make obvious that NNRTI which are used as anti-HIV drugs could also be used as to target telomerase reverse transcriptase in cancer cells. hTERT is composed of four domains which are known as NTerminal, RNA binding domain, RT domain, and C-Terminal domain. It is possible to find out the best NNRTI against cancer cell control by docking all available NNRTI against this RT domain of hTERT. Due to the lack of crystallographic and NMR structure of this hTERT, the domain docking approach was handled to overcome structure deficit. This study focused on available NNRTI, to find out the better NNRTI to use as anti-cancer leads or precursor compounds.